WO2023023152 - THERMOSTABLE LIPID NANOPARTICLE AND METHODS OF USE THEREOF
National phase entry:
Publication Number
WO/2023/023152
Publication Date
23.02.2023
International Application No.
PCT/US2022/040596
International Filing Date
17.08.2022
Title **
[English]
THERMOSTABLE LIPID NANOPARTICLE AND METHODS OF USE THEREOF
[French]
NANOPARTICULE LIPIDIQUE THERMOSTABLE ET SES MÉTHODES D'UTILISATION
Applicants **
MERCK SHARP & DOHME LLC
BETT, Andrew
RAHEEM, Izzat
SKUDLAREK, Jason, W.
STRABLE, Erica, L.
Inventors
BETT, Andrew
RAHEEM, Izzat
SKUDLAREK, Jason, W.
STRABLE, Erica, L.
Priority Data
63/235,014
19.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4323 | |
| EPO | Filing, Examination, Granting | 40379 | |
| Japan | Filing, Examination, Granting | 3493 | |
| South Korea | Filing, Examination, Granting | 4724 | |
| USA | Filing, Examination, Granting | 20440 |
Total:
73,359
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides, among other things, a lipid nanoparticle adjuvant composition. The present disclosure provides pharmaceutical compositions that include a stable lipid nanoparticle adjuvant and human papillomavirus (HPV) virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.[French]
La présente divulgation concerne, entre autres, une composition d'adjuvant de nanoparticules lipidiques. La présente divulgation concerne des compositions pharmaceutiques qui comprennent un adjuvant de nanoparticules lipidiques stables et des particules pseudo-virales (VLP) d'un papillomavirus humain (HPV) d'au moins un type de papillomavirus humain (HPV) choisi dans le groupe constitué par les types de HPV : 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73 et 82.